Abstract:The gastrointestinal (GI) tract is the largest absorption organ in the body and is also enriched with many of the Xenobiotic Processing Genes (XPGs) , which play an important role in xenobiotic bioactivation, metabolism, and detoxification. The application of genetically modified mouse models to study drug metabolism and toxicity has proven beneficial over the past decade, and with the ability to culture primary cells from these animal experiments can now be developed in vitro to examine mechanistic properties. Intestinal stem cells (ISCs), located in the crypt zone at the bottom of the villi, produce and differentiate into intestinal epithelial cells (IECs) as a supply for continuous intestinal renewal. Methods have been established in long‐term culture conditions in which one single Lgr5+ stem cell embedded in matrix gel can independently generate villus‐like epithelial domains with the presence of all differentiated IECs. Here, we report the application of 3D crypt organoid cultures as a tool for the study of intestinal drug metabolism and toxicity evaluation. Crypt cells were isolated from mouse intestinal tissue, suspended into matrigels, and cultured in the advanced DMEM/F12 medium supplemented with growth factors. Following continuous budding, crypts were further expanded to create organoids and the function of genes and enzymes involved in drug metabolism were evaluated. Crypt cultures were treated with vehicle (control) or different prototypical agonists of the xenobiotic nuclear receptors (XNR), including the AhR agonist TCDD, PXR agonist PCN, CAR agonist TCPOBOP, PPARa agonist Wy14643, and LXRa agonist T0901317. RT‐QPCR results demonstrated that in response to the different XNR agonists, the representative downstream target genes, including Cyp1a1 (by TCDD), Cyp3a11 (by PCN), Cyp2b10 (by TCPOBOP), Cyp4a10 (by Wy14643), and Abca1 (by T0901317) were largely induced. To further validate receptor‐specific gene induction by their corresponding ligands, we validated these findings using XNR‐null mice. In crypts isolated from Pxr −/− , PCN failed to induce Cyp3a11 gene expression; similarly, TCPOBOP and Wy14643 failed to induce Cyp2b10 or Cyp4a10 in the crypt organoids isolated from Car −/− and Ppara −/− mice, respectively. Camptothecin (CPT)‐11 (Irinotecan), an anticancer drug that generates substantial intestinal toxicity, is bioactivated by carboxylesterases to form the active topoisomerase 1 inhibitor SN‐38. Previous studies in our laboratory have shown that the deletion of intestinal UGT1A1 greatly sensitizes mice toward irinotecan induced intestinal toxicity induced by SN‐38. Bioactivation of irinotecan and cytotoxicity of SN‐38 can also be evaluated in novel crypt organoid cultures. This study suggests that crypt organoid cultures can be exploited as an effective in vitro model for studying the impact of xenobiotics on intestinal XPGs , drug metabolism, and toxicity. Support or Funding Information Supported by ES010337 and ES024818.

Xenogeneic-Free Human Intestinal Organoids for Assessing Intestinal Nutrient Absorption

Intestinal organoids: A thriving and powerful tool for investigating dietary nutrients-intestinal homeostasis axis

Establishment of human intestinal organoids derived from commercially available cryopreserved intestinal epithelium and evaluation for pharmacokinetic study

Usefulness of Human Jejunal Spheroid–Derived Differentiated Intestinal Epithelial Cells for the Prediction of Intestinal Drug Absorption in Humans

A Novel Model of P‐Glycoprotein Inhibitor Screening Using Human Small Intestinal Organoids

Functional intestinal monolayers from organoids derived from human iPS cells for drug discovery research

Development of an Evaluation System Using Intestinal Organoids for Drug Efflux Transport Analysis by an Imaging Approach

3D organoids derived from the small intestine: An emerging tool for drug transport research

Novel In Vitro Models for Cell Differentiation and Drug Transport Studies of the Human Intestine

Establishment of an Apical-Out Organoid Model for Directly Assessing the Function of Postbiotics

Toward Xeno-Free Differentiation of Human Induced Pluripotent Stem Cell-Derived Small Intestinal Epithelial Cells

Simultaneous Evaluation of Membrane Permeability and UDP-Glucuronosyltransferase–Mediated Metabolism of Food-Derived Compounds Using Human Induced Pluripotent Stem Cell–Derived Small Intestinal Epithelial Cells

Crypt Organoids Culture as an In Vitro Model in Studying Regulation of Xenobiotic Metabolism and drug‐induced Cytotoxicity

Regulation of Enterocyte Brush Border Membrane Primary Na-Absorptive Transporters in Human Intestinal Organoid-Derived Monolayers

Human small intestinal organotypic culture model for drug permeation, inflammation, and toxicity assays

Combining Human Organoids and Organ-on-a-Chip Technology to Model Intestinal Region-Specific Functionality.

Organoid-derived Duodenum Intestine-Chip for preclinical drug assessment in a human relevant system

Evaluation of Tissue Stem Cell-Derived Human Intestinal Organoids, a Physiologically Relevant Model to Evaluate Cytochrome P450 Induction in Gut

An In Vitro Small Intestine Model Incorporating a Food Matrix and Bacterial Mock Community for Intestinal Function Testing

A simple three-dimensional gut model constructed in a restricted ductal microspace induces intestinal epithelial cell integrity and facilitates absorption assays

Development and Characterization of an In Vitro Intestinal Model Including Extracellular Matrix and Macrovascular Endothelium